Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) for the reporting period ending June 30, 2010. The filing addresses a material definitive agreement termination involving the Company and the National Institute of Allergy and Infectious Diseases (NIAID).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It references a separate, active contract valued at $15.9 million for the advanced development of Valortim as an anti-toxin therapeutic.
Material Changes
- Termination of 3G Contract: On June 30, 2010, the Company and NIAID modified their existing three-year contract (HHSN272200800049C) related to the third-generation anthrax vaccine program. This modification terminates the contract as part of a no-cost settlement.
- Continued Valortim Contract: A separate $15.9 million contract for the advanced development of Valortim remains in full force and effect.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the termination of the 3G Contract. The settlement was executed at no cost to the Company.
Investor Verification Checklist
- Confirm the impact of the terminated 3G Contract on the Company's overall pipeline and future revenue projections.
- Verify the status and milestones of the active $15.9 million Valortim contract.
- Review subsequent filings for any financial impact resulting from the no-cost settlement.